http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001518890-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-14 |
| filingDate | 1998-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001518890-A |
| titleOfInvention | Quinoline derivatives as inhibitors of HIV integrase |
| abstract | (57) [Summary] The present invention relates to a quinoline derivative corresponding to the formula (I). In this formula, R a , R b and R c are the same or different from each other and represent the same or different, occupy any position of each ring, and represent one or more substituents; these one or more substituents, - (CH 2) n -Y or -CH = CH-Y group (wherein Y is halogen atom), - OH, -OR, -COH , -COR, -COOH, COOR, -COH, -COR, -CONH 2 , -CON (R x, R y), - CH = NOH, -CO-CH = NOH, -NH 2, -N (R x, R y), - NO 2, -PO (oR) 2, -SH 2, -SR, -SO 2 R, -SO 2 NHR, CN or Z (R c) (where R is 1-8 alkyl carbon atoms,, Or represents an aryl group or a heterocyclic group, R x and R y are the same or different and represent an alkyl group having 1 to 5 carbon atoms, Z represents an aryl group or a heterocyclic group, n represents 0 or selected from among the group of 1 of an integer), R b may additionally represent a hydrogen atom, and, Y is -R c Z represents a COOH or -COOR group in formula (I), if it represents an aryl group, has at least three substituents, or the quinoline nucleus is trisubstituted, and X represents an ethylene double bond. Or — (CH 2 ) n (where n is an integer of 1 to 5), —CH (R d ) —CH (R e ) (where R d and R e are the same or different, and represents a halogen atom, a hydroxyl group or an epoxy group), or - (CH 2) n '-OC (O) - (CH 2) m -, - (CH 2) n' -C (O) -O- (CH 2 ) m -,-(CH 2 ) n '-O- (CH 2 ) m -,-(CH 2 ) n ' -N (Q)-(CH 2 ) m- or-(CH 2 ) n '- S (O) t - (CH 2) m - ( wherein n 'is 0-8 integer, m is 0-8 integer, t is 0 or an integer of 1 or 2, and Q is a hydrogen atom or an alkyl, A group or an aryl group). The present invention also relates to the pharmacologically acceptable salts of these derivatives, their diastereoisomeric and enantiomeric forms. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8710230-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008542352-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013533885-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4827986-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013241410-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011503116-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011503119-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014055129-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011503117-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011503118-A |
| priorityDate | 1997-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 177.